Issuu on Google+

Companion Diagnostics Market - Global Industry Trends, Analysis and Forecast 2017 - 2024

Publisher : Coherent Market Insights Single User license:

USD 4500

Publication Date: Feb 2017

Site User License:

USD 7000

Number of Pages: 200

Enterprisewide User license: USD 10000 Contact us : info@marketreportscenter.com call: 1-646-883-3044


What’s CDx ? • Companion diagnostic (CDx) is a diagnostic tool used to determine the suitability of a drug therapy to the patient. It has become a critical part of targeted cancer therapy that allows for development of personalized therapy can be developed and administered to the patient. Whole blood samples, tissues samples, or buccal samples are collected and tested for diagnosis and identification of targeted disease biomarker. CDx is usually utilized in identifying genetic mutations and the health and treatment approach implications. • In July 2016, the U.S. FDA released a draft guideline for development of a therapeutic product accompanying an IVD companion diagnostic. Companion diagnostics include Gleevec (imatinib mesylate) and BCR-ABL LDT and DAKO C-KIT PharmDx, Herceptin (trastuzumab) and DAKO Herceptest; and Nolvaldex (tamoxifen) and laboratory-developed estrogen receptor positive test.

Contact us : info@marketreportscenter.com call: 1-646-883-3044


Market Dynamics Companion diagnostics are beneficial for pharmaceutical companies who face challenges with respect to high drug development cost, safety and outcome of clinical trials, and long product approval time. Companion diagnostics lowers development costs, improves time to market and enhances drug safety by enabling rapid identification of target biomarker and the most effective drug therapy. For patients, the technology provides better treatment outcomes and lower morbidity risk. Use of technologies such as PCR, immunohistochemistry, and gene sequencing has enabled accurate diagnosis and determination of targeted cancer therapy. As the CDx tests also aid in revealing the off-target effects of a drug along with identification of a molecular target, CDx have become and indispensable tool for oncologists.

Contact us : info@marketreportscenter.com call: 1-646-883-3044


Market Taxonomy This report segments the global companion diagnostics market on the basis of application, technology, and geography. On the basis of application, the market is categorized into breast cancer, lung cancer, colorectal cancer, gastric cancer, melanoma, and others. On the basis of technology, the market is segmented into immunohistochemistry, real-time PCR, gene sequencing, Fluorescence in situ hybridization (FISH), and others. For comprehensive understanding of market dynamics, the global companion diagnostics market is analyzed across key geographical regions namely North America, Europe, Asia Pacific, Latin America, Africa, and Middle East. Each of these regions is analyzed on basis of market findings across major countries in these regions for a macro-level understanding of the market.

Contact us : info@marketreportscenter.com call: 1-646-883-3044


What Segmentation is covered in report? Global Companion Diagnostics Market, By Application: o Breast Cancer o Lung Cancer o Colorectal Cancer o Gastric Cancer o Melanoma o Others

• Global Companion Diagnostics Market, By Geography: o North America o Europe o Asia-Pacific o Latin America o Middle East o Africa

Global Companion Diagnostics Market, By Technology: o Immunohistochemistry o Real-time PCR o Gene Sequencing o FISH o Others

Contact us : info@marketreportscenter.com call: 1-646-883-3044


Key takeaways of the market: The global companion diagnostic market is expected to expand at a CAGR of 12% during the forecast period (2016–2024). Improved clinical outcomes, reduced total research cost and faster time to market are some of the major factors driving collaborations and CDx development globally The breast cancer application in the global CDx market was estimated to be the largest in 2015 and is expected to dominate the market throughout the forecast period in terms of value. This is owing to high number of approved brands with CDx tests, driving adoption of these products in treatment of breast cancer. In terms of technology, the gene sequencing method segment is expected to expand at a CAGR of 12.6% during the forecast period. Growth of the segment is mainly attributed to increasing focus on identification of genetic mutations that can help in precise identification of the treatment approach for cancer therapies. The global companion diagnostics market is characterized by strategic research and development collaborations among the drug and diagnostic test developers. According to the Wildwood Ventures Ltd., the number of global deal in CDx market has increased from 13 in 2007 to 66 in 2013. Contact us : info@marketreportscenter.com call: 1-646-883-3044


What are companies profiled in report? Some of the major players are Abbott Laboratories, Inc., Agilent Technologies, Inc., Danaher Corporation, GE Healthcare, Qiagen N.V., Roche Diagnostics, BiomĂŠrieux, Myriad Genetics, Inc., bioMĂŠrieux SA, and Siemens Healthcare. Contact us : info@marketreportscenter.com call: 1-646-883-3044


• Full Report at :https://marketreportscenter.com/reports/508244/companiondiagnostics-market-global-industry-trends-analysis-and-forecast-2017-2024 • Reach us at: info@marketreportscenter.com • Visit us : www.marketreportscenter.com • Call us at : 1-646-883-3044 (US)

• Follow us: Facebook Twitter Linkedin


Companion diagnostics Market Trends, Growth, Application and Forecasts To 2024